StreetInsider.com News Articles

Silexion Therapeutics faces Nasdaq delisting over equity shortfall

Fri, 21 Aug 2026 16:23:44 -0400

Silexion Therapeutics Corp (NASDAQ: SLXN) received a delisting notice from the Nasdaq Listing Qualifications Department on August 18, 2026, for failing to meet the minimum shareholders' equity requirement for continued listing on The Nasdaq Capital Market.

The notice relates to non-compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed under the Equity Standard to maintain at least $2,500,000 in shareholders' equity. Silexion reported shareholders' equity of $44,000 in its Form 10-Q for the period ended June 30, 2026, and does not currently meet any alternative continued listing standards.

The company stated it believed it had restored compliance as of the August

Form 8-K Silexion Therapeutics For: Aug 21

Fri, 21 Aug 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260821/26961679.html

Form 8-K Silexion Therapeutics For: Aug 21

Fri, 21 Aug 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260821/26961679.html

Form SCHEDULE 13D/A Silexion Therapeutics Filed by: Moringa Sponsor, LP

Wed, 19 Aug 2026 20:19:00 -0400

si-local-file:///var/storage/secattach/20260819/26951597.html

Form SCHEDULE 13D/A Silexion Therapeutics Filed by: Moringa Sponsor, LP

Wed, 19 Aug 2026 20:19:00 -0400

si-local-file:///var/storage/secattach/20260819/26951597.html

Form SCHEDULE 13G Silexion Therapeutics Filed by: INTRACOASTAL CAPITAL, LLC

Tue, 18 Aug 2026 17:37:00 -0400

si-local-file:///var/storage/secattach/20260818/26945621.html

Form SCHEDULE 13G Silexion Therapeutics Filed by: INTRACOASTAL CAPITAL, LLC

Tue, 18 Aug 2026 17:37:00 -0400

si-local-file:///var/storage/secattach/20260818/26945621.html

Form PRE 14A Silexion Therapeutics For: Aug 14

Fri, 14 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260814/26931536.html

Form PRE 14A Silexion Therapeutics For: Aug 14

Fri, 14 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260814/26931536.html

Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c

Fri, 14 Aug 2026 10:00:22 -0400

Silexion Therapeutics (NASDAQ: SLXN) reported Q2 EPS of ($5.17), $7.93 better than the analyst estimate of ($13.10).

For earnings history and earnings-related data on Silexion Therapeutics (SLXN) click here.

Form 10-Q Silexion Therapeutics For: Jun 30

Fri, 14 Aug 2026 09:12:00 -0400

si-local-file:///var/storage/secattach/20260814/26925653.html

Form 10-Q Silexion Therapeutics For: Jun 30

Fri, 14 Aug 2026 09:12:00 -0400

si-local-file:///var/storage/secattach/20260814/26925653.html

Form 8-K Silexion Therapeutics For: Aug 14

Fri, 14 Aug 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260814/26925547.html

Form 8-K Silexion Therapeutics For: Aug 14

Fri, 14 Aug 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260814/26925547.html

Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Fri, 14 Aug 2026 08:45:00 -0400

Successfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center in July 2026 following clinical trial authorizations from regulators in both Israel and Germany

Expanded the therapeutic profile of SIL204 with new preclinical immuno-oncology data supporting a coordinated immune-sensitization signature across three key immune pathways and four KRAS mutations, reinforcing the rationale for future combination with anti-PD-(L)1 checkpoint inhibitor therapies

Advanced operational and financial readiness for the Phase 2/3 program, including initiation of GMP clinical supply manufacturing with

Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Fri, 14 Aug 2026 08:45:00 -0400

Successfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center in July 2026 following clinical trial authorizations from regulators in both Israel and Germany

Expanded the therapeutic profile of SIL204 with new preclinical immuno-oncology data supporting a coordinated immune-sensitization signature across three key immune pathways and four KRAS mutations, reinforcing the rationale for future combination with anti-PD-(L)1 checkpoint inhibitor therapies

Advanced operational and financial readiness for the Phase 2/3 program, including initiation of GMP clinical supply manufacturing with

Form 8-K Silexion Therapeutics For: Aug 13

Thu, 13 Aug 2026 17:06:00 -0400
si-local-file:///var/storage/secattach/20260813/26922610.html

Form 8-K Silexion Therapeutics For: Aug 13

Thu, 13 Aug 2026 17:06:00 -0400
si-local-file:///var/storage/secattach/20260813/26922610.html

Form 8-K Silexion Therapeutics For: Aug 13

Thu, 13 Aug 2026 16:03:00 -0400
si-local-file:///var/storage/secattach/20260813/26920607.html

Form 8-K Silexion Therapeutics For: Aug 13

Thu, 13 Aug 2026 16:03:00 -0400
si-local-file:///var/storage/secattach/20260813/26920607.html

Form 424B4 Silexion Therapeutics

Thu, 13 Aug 2026 11:01:00 -0400
si-local-file:///var/storage/secattach/20260813/26918423.html

Form 424B4 Silexion Therapeutics

Thu, 13 Aug 2026 11:01:00 -0400
si-local-file:///var/storage/secattach/20260813/26918423.html

Form SCHEDULE 13G/A Silexion Therapeutics Filed by: INTRACOASTAL CAPITAL, LLC

Thu, 13 Aug 2026 10:22:00 -0400
si-local-file:///var/storage/secattach/20260813/26918147.html

Form SCHEDULE 13G/A Silexion Therapeutics Filed by: INTRACOASTAL CAPITAL, LLC

Thu, 13 Aug 2026 10:22:00 -0400
si-local-file:///var/storage/secattach/20260813/26918147.html

Form EFFECT Silexion Therapeutics

Wed, 12 Aug 2026 06:05:00 -0400
si-local-file:///var/storage/secattach/20260812/26908331.html